$1.41
1.40% yesterday
Nasdaq, Nov 05, 10:05 pm CET
ISIN
US67577C1053
Symbol
OCGN

Ocugen Inc Stock price

$1.41
-0.41 22.53% 1M
+0.65 85.53% 6M
+0.61 75.16% YTD
+0.46 48.41% 1Y
-0.12 7.84% 3Y
+1.12 391.46% 5Y
-247.60 99.43% 10Y
-703.59 99.80% 20Y
Nasdaq, Closing price Wed, Nov 05 2025
-0.02 1.40%
ISIN
US67577C1053
Symbol
OCGN
Industry

Key metrics

Basic
Market capitalization
$440.4m
Enterprise Value
$441.4m
Net debt
$1.0m
Cash
$27.0m
Shares outstanding
292.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
92.7 | 123.3
EV/Sales
92.9 | 123.6
EV/FCF
negative
P/B
144.4
Financial Health
Equity Ratio
35.9%
Return on Equity
-182.4%
ROCE
-155.6%
ROIC
-
Debt/Equity
9.2
Financials (TTM | estimate)
Revenue
$4.8m | $3.6m
EBITDA
$-52.3m | -
EBIT
$-55.4m | $-59.8m
Net Income
$-56.9m | $-62.6m
Free Cash Flow
$-52.3m
Growth (TTM | estimate)
Revenue
-48.4% | -12.0%
EBITDA
16.7% | -
EBIT
13.4% | -9.3%
Net Income
9.3% | -15.8%
Free Cash Flow
4.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,101.0% | -
EBIT
-1,165.1%
Net
-1,197.7% | -1,752.2%
Free Cash Flow
-1,100.2%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
18.9%
Employees
95
Rev per Employee
$40.0k
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Ocugen Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Ocugen Inc forecast:

Buy
91%
Hold
9%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.75 4.75
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
26% 26%
543%
- Research and Development Expense 34 34
11% 11%
723%
-52 -52
17% 17%
-1,102%
- Depreciation and Amortization 3.05 3.05
175% 175%
64%
EBIT (Operating Income) EBIT -55 -55
13% 13%
-1,166%
Net Profit -57 -57
9% 9%
-1,199%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Neutral
Seeking Alpha
about 17 hours ago
Ocugen, Inc. ( OCGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim G...
Neutral
GlobeNewsWire
one day ago
Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA) Executed licensing agreement with Kwangdong Pharmaceutical for exclusive rights in So...
Neutral
GlobeNewsWire
14 days ago
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025.
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 95
Founded 2013
Website ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today